This smallcap stock has surged 25 per cent in five trading sessions

It was up by 15 per cent in yesterday’s trading session alone.

Lasa Supergenerics which specialises in ‘catalyst chemistry’, is gaining good momentum over the last few days.  It was up by 15 per cent in yesterday’s trading session alone. The reason for such a rise in share price is better than expected results for Q4FY22. The company posted a net profit of Rs 12.28 crore for the period ended March 31, 2022, against a loss of Rs 4.71 crores for the period ended December 31, 2021. In the same period (Q4FY22) company has reported a total income of Rs 51.22 crore as compared to Rs 15.75 crore during the period ended December 31, 2021. It increased by more than three times sequentially. A final dividend of Rs 0.25 (2.5 per cent) per equity share for the financial year ended March 31, 2022, has also been announced.  

The company is also one of the largest manufacturers of Albendazole, Fenbendazole, Oxfendazole and Ricobendazole. It exports products across Australia, Bangladesh, China, Turkey, Egypt, and Jordan among others. They have four state-of-the-art manufacturing facilities located in Maharashtra with a total capacity of 4,700 TPA and a volumetric capacity of 5,300 TPA. Currently, it is operating at 95 per cent. It has also announced the launch of two new products Oxycozanide and Paracetamol.